US FDA Approves Regeneron's Libvyssi for Generalized Myasthenia Gravis
REGN Regeneron Pharmaceuticals Inc
$920.69 -0.29%
View chart & analysis → - 1The US Food and Drug Administration has approved Libvyssi, a treatment for generalized myasthenia gravis developed by Regeneron.
- 2Regeneron's drug, with an annual supply price of approximately $410,000, is the first autoimmune disease treatment among the eight RNAi therapies launched in the market prior to Libvyssi's approval.
- 3Alnylam Pharmaceuticals will receive a $25 million milestone payment related to the approval of Libvyssi.
So what's the key point?
The US Food and Drug Administration approved a new disease treatment from Regeneron. Regeneron has released a new therapy, and Alnylam will receive $25 million.
Source BioPharma Dive · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.